VVOS vs. SRTS, ICAD, HYPR, LUCD, MGRM, NTRB, NSPR, GUTS, ICCM, and CTSO
Should you be buying Vivos Therapeutics stock or one of its competitors? The main competitors of Vivos Therapeutics include Sensus Healthcare (SRTS), iCAD (ICAD), Hyperfine (HYPR), Lucid Diagnostics (LUCD), Monogram Orthopaedics (MGRM), Nutriband (NTRB), InspireMD (NSPR), Fractyl Health (GUTS), IceCure Medical (ICCM), and Cytosorbents (CTSO). These companies are all part of the "medical equipment" industry.
Vivos Therapeutics vs.
Sensus Healthcare (NASDAQ:SRTS) and Vivos Therapeutics (NASDAQ:VVOS) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, community ranking, profitability, earnings, institutional ownership, analyst recommendations, valuation, dividends and media sentiment.
Sensus Healthcare currently has a consensus price target of $14.67, suggesting a potential upside of 172.61%. Vivos Therapeutics has a consensus price target of $6.30, suggesting a potential upside of 101.92%. Given Sensus Healthcare's stronger consensus rating and higher probable upside, equities analysts plainly believe Sensus Healthcare is more favorable than Vivos Therapeutics.
Sensus Healthcare has higher revenue and earnings than Vivos Therapeutics. Vivos Therapeutics is trading at a lower price-to-earnings ratio than Sensus Healthcare, indicating that it is currently the more affordable of the two stocks.
Sensus Healthcare has a net margin of 15.90% compared to Vivos Therapeutics' net margin of -86.19%. Sensus Healthcare's return on equity of 12.60% beat Vivos Therapeutics' return on equity.
25.3% of Sensus Healthcare shares are held by institutional investors. Comparatively, 26.4% of Vivos Therapeutics shares are held by institutional investors. 9.4% of Sensus Healthcare shares are held by insiders. Comparatively, 3.0% of Vivos Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Sensus Healthcare received 169 more outperform votes than Vivos Therapeutics when rated by MarketBeat users. Likewise, 68.66% of users gave Sensus Healthcare an outperform vote while only 57.69% of users gave Vivos Therapeutics an outperform vote.
In the previous week, Sensus Healthcare and Sensus Healthcare both had 1 articles in the media. Sensus Healthcare's average media sentiment score of 1.27 beat Vivos Therapeutics' score of 0.00 indicating that Sensus Healthcare is being referred to more favorably in the media.
Sensus Healthcare has a beta of 1.24, meaning that its stock price is 24% more volatile than the S&P 500. Comparatively, Vivos Therapeutics has a beta of 7.47, meaning that its stock price is 647% more volatile than the S&P 500.
Summary
Sensus Healthcare beats Vivos Therapeutics on 16 of the 18 factors compared between the two stocks.
Get Vivos Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for VVOS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Vivos Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:VVOS) was last updated on 2/24/2025 by MarketBeat.com Staff
Free VVOS Stock Alerts